322 related articles for article (PubMed ID: 16162020)
1. Optimal pharmacological therapy for community-acquired pneumonia: the role of dual antibacterial therapy.
Epstein BJ; Gums JG
Drugs; 2005; 65(14):1949-71. PubMed ID: 16162020
[TBL] [Abstract][Full Text] [Related]
2. The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia.
Weiss K; Tillotson GS
Chest; 2005 Aug; 128(2):940-6. PubMed ID: 16100190
[TBL] [Abstract][Full Text] [Related]
3. Fluoroquinolones or macrolides alone versus combined with β-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis.
Raz-Pasteur A; Shasha D; Paul M
Int J Antimicrob Agents; 2015 Sep; 46(3):242-8. PubMed ID: 26092096
[TBL] [Abstract][Full Text] [Related]
4. Effect of β-Lactam Plus Macrolide Versus Fluoroquinolone on 30-Day Readmissions for Community-Acquired Pneumonia.
Gilbert TT; Arfstrom RJ; Mihalovic SW; Dababneh AS; Varatharaj Palraj BR; Dierkhising RA; Mara KC; Lessard SR
Am J Ther; 2020; 27(2):e177-e182. PubMed ID: 30418221
[TBL] [Abstract][Full Text] [Related]
5. The science of selecting antimicrobials for community-acquired pneumonia (CAP).
File TM
J Manag Care Pharm; 2009 Mar; 15(2 Suppl):S5-11. PubMed ID: 19236135
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of combination therapy versus monotherapy with a third-generation cephalosporin in bacteraemic pneumococcal pneumonia: A propensity score analysis.
De la Calle C; Ternavasio-de la Vega HG; Morata L; Marco F; Cardozo C; García-Vidal C; Del Rio A; Cilloniz C; Torres A; Martínez JA; Mensa J; Soriano A
J Infect; 2018 Apr; 76(4):342-347. PubMed ID: 29360520
[TBL] [Abstract][Full Text] [Related]
7. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia.
Lodise TP; Kwa A; Cosler L; Gupta R; Smith RP
Antimicrob Agents Chemother; 2007 Nov; 51(11):3977-82. PubMed ID: 17709460
[TBL] [Abstract][Full Text] [Related]
8. Respiratory fluoroquinolone monotherapy vs. β-lactam plus macrolide combination therapy for hospitalized adults with community-acquired pneumonia: A systematic review and meta-analysis of randomized controlled trials.
Choi SH; Cesar A; Snow TAC; Saleem N; Arulkumaran N; Singer M
Int J Antimicrob Agents; 2023 Sep; 62(3):106905. PubMed ID: 37385561
[TBL] [Abstract][Full Text] [Related]
9. Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point.
File TM; Eckburg PB; Talbot GH; Llorens L; Friedland HD
Int J Antimicrob Agents; 2017 Aug; 50(2):247-251. PubMed ID: 28599867
[TBL] [Abstract][Full Text] [Related]
10. Community-Acquired Pneumonia in Adults: Diagnosis and Management.
Kaysin A; Viera AJ
Am Fam Physician; 2016 Nov; 94(9):698-706. PubMed ID: 27929242
[TBL] [Abstract][Full Text] [Related]
11. How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community-acquired pneumonia? A systematic review.
Oosterheert JJ; Bonten MJ; Hak E; Schneider MM; Hoepelman IM
J Antimicrob Chemother; 2003 Oct; 52(4):555-63. PubMed ID: 12972448
[TBL] [Abstract][Full Text] [Related]
12. Does empirical therapy with a fluoroquinolone or the combination of a β-lactam plus a macrolide result in better outcomes for patients admitted to the general ward?
Ruhe J; Mildvan D
Infect Dis Clin North Am; 2013 Mar; 27(1):115-32. PubMed ID: 23398869
[TBL] [Abstract][Full Text] [Related]
13. Initial antibiotic selection and patient outcomes: observations from the National Pneumonia Project.
Bratzler DW; Ma A; Nsa W
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S193-201. PubMed ID: 18986289
[TBL] [Abstract][Full Text] [Related]
14. Appropriate outpatient macrolide use in community-acquired pneumonia.
Gotfried MH
J Am Acad Nurse Pract; 2004 Apr; 16(4):146, 148, 150 passim. PubMed ID: 15137473
[TBL] [Abstract][Full Text] [Related]
15. Cardiac events after macrolides or fluoroquinolones in patients hospitalized for community-acquired pneumonia: post-hoc analysis of a cluster-randomized trial.
Postma DF; Spitoni C; van Werkhoven CH; van Elden LJR; Oosterheert JJ; Bonten MJM
BMC Infect Dis; 2019 Jan; 19(1):17. PubMed ID: 30612559
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia].
Karaboğa B; Çilli A
Tuberk Toraks; 2015 Jun; 63(2):94-101. PubMed ID: 26167966
[TBL] [Abstract][Full Text] [Related]
17. Antibiotic treatment of moderate-severe community-acquired pneumonia: design and rationale of a multicentre cluster-randomised cross-over trial.
van Werkhoven CH; Postma DF; Oosterheert JJ; Bonten MJ
Neth J Med; 2014 Apr; 72(3):170-8. PubMed ID: 24846935
[TBL] [Abstract][Full Text] [Related]
18. Antibiotic treatment of community acquired pneumonia varies widely across Germany.
Kohlhammer Y; Raspe H; Marre R; Suttorp N; Welte T; Schäfer T;
J Infect; 2007 May; 54(5):446-53. PubMed ID: 17007933
[TBL] [Abstract][Full Text] [Related]
19. Update on the combination effect of macrolide antibiotics in community-acquired pneumonia.
Emmet O'Brien M; Restrepo MI; Martin-Loeches I
Respir Investig; 2015 Sep; 53(5):201-9. PubMed ID: 26344609
[TBL] [Abstract][Full Text] [Related]
20. Initial use of one or two antibiotics for critically ill patients with community-acquired pneumonia: impact on survival and bacterial resistance.
Adrie C; Schwebel C; Garrouste-Orgeas M; Vignoud L; Planquette B; Azoulay E; Kallel H; Darmon M; Souweine B; Dinh-Xuan AT; Jamali S; Zahar JR; Timsit JF;
Crit Care; 2013 Nov; 17(6):R265. PubMed ID: 24200097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
